Novo Nordisk (NYSE:NVO) said Tuesday it has entered into a strategic collaboration with OpenAI to deploy advanced artificial intelligence tools across its business, spanning drug discovery through to commercial operations.
The Danish pharmaceutical group said the partnership will support the analysis of complex datasets, help identify potential drug candidates, and shorten the timeline from early-stage research to patient access. It added that the initiative will operate under strict safeguards, including data protection, governance frameworks, and human oversight.
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare,” said Mike Doustdar. He added that millions of people living with obesity and diabetes require improved treatment options, and that integrating AI will enable the company to process data at unprecedented scale and test scientific hypotheses more rapidly.
OpenAI will also support workforce development at Novo Nordisk by enhancing AI-related skills and literacy across its global employee base. In addition, the collaboration will extend to improving efficiency in manufacturing, supply chains, distribution, and broader corporate functions.
Initial pilot projects are set to roll out across research and development, manufacturing, and commercial units, with full implementation targeted by the end of 2026.
“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” said Sam Altman. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
The agreement builds on Novo Nordisk’s existing AI efforts, which already include partnerships with technology firms and research institutions. The company employs around 68,800 people across 80 countries and sells its products in approximately 170 markets worldwide.